Latest Can-Fite Stories
- Glaucoma Phase II ongoing study will enroll patients to the next higher dose without an interim analysis, no safety issues have been recorded PETACH TIKVA, Israel, June 9, 2014 /PRNewswire/
PETACH TIKVA, Israel, Feb.
The patent confers exclusive right for the manufacturing of CF101 in Japan until 2028 and bolsters license agreement that Can-Fite has already signed in Japan PETACH TIKVA, Israel,
OneMedForum San Francisco 2014 on January 13th PETACH TIKVA, Israel, Jan.
Following the Successful Utilization of A3 Adenosine Receptor Biomarker in Can-Fite's Phase IIb Rheumatoid Arthritis Study PETACH TIKVA, Israel, Dec.
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.